Obesity and Breast Cancer Outcomes: How Much Evidence Is Needed to Change Practice?
JOURNAL OF CLINICAL ONCOLOGY (2016)
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 34, Issue 7, Pages 646-+Publisher
AMER SOC CLINICAL ONCOLOGY
Keywords
Categories
Ask authors/readers for more resources
Authors
I am an author on this paper
Reviews
Recommended
How Much Technological Progress is Needed to Make Solar Hydrogen Cost-Competitive?
Jacob Schneidewind
ADVANCED ENERGY MATERIALS (2022)
How Much Communication Resource is Needed to Run a Wireless Blockchain Network?
Lei Zhang, Hao Xu, Oluwakayode Onireti, Muhammad Ali Imran, Bin Cao
IEEE NETWORK (2022)
Chest X-Ray Diagnostic Quality Assessment: How Much Is Pixel-Wise Supervision Needed?
Junhao Hu, Chenyang Zhang, Kang Zhou, Shenghua Gao
IEEE TRANSACTIONS ON MEDICAL IMAGING (2022)
How much is policy driving the adoption of cover crops? Evidence from four EU regions
Jonas Kathage, Bert Smit, Bas Janssens, Wiepie Haagsma, Jose Luis Adrados
LAND USE POLICY (2022)
Oil at sea-how much is too much?
Ira Leifer
SCIENCE (2022)
How much time is needed in clinical practice to reach a diagnosis of clinically established Parkinson's disease?
Malco Rossi, Santiago Perez-Lloret, Marcelo Merello
PARKINSONISM & RELATED DISORDERS (2021)
Positioning of grid points for spanning potential energy surfaces-How much effort is really needed?
Moritz Schneider, Daniel Born, Johannes Kaestner, Guntram Rauhut
JOURNAL OF CHEMICAL PHYSICS (2023)
Preoperative Radiation for Soft Tissue Sarcomas: How Much Is Needed?
Safia K. Ahmed, Ivy A. Petersen
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2022)
How much smart is smart?
Christoph Heilmann, David Wozabal
APPLIED ENERGY (2021)
How much vocabulary is needed for comprehension of video lectures in MOOCs: A corpus-based study
Ismail Xodabande, Hourieh Ebrahimi, Sedigheh Karimpour
FRONTIERS IN PSYCHOLOGY (2022)
How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review
Leiah J. Brigitha, Rob Pieters, Inge M. van der Sluis
EUROPEAN JOURNAL OF CANCER (2021)
How much narcotics are really needed after bariatric surgery: results of a prospective study
Rickesha Wilson, Sayf A. Said, Susan Rydzinski, Jesse Gutnick, Ali Aminian, Toms Augustin
SURGERY FOR OBESITY AND RELATED DISEASES (2023)
Hydroxyurea: how much is enough?
Charles T. Quinn
BLOOD (2023)
A multiscale perspective on how much wetland restoration is needed to achieve targets for ecosystem services
Stephanie Tomscha, Bethanna Jackson, Rubianca Benavidez, Mairead de Roiste, Stephen Hartley, Julie Deslippe
ECOSYSTEM SERVICES (2023)
Reversing declines in farmland birds: How much agri-environment provision is needed at farm and landscape scales?
Elwyn Sharps, Robert W. Hawkes, Andrew J. Bladon, David L. Buckingham, Jennifer Border, Antony J. Morris, Philip V. Grice, Will J. Peach
JOURNAL OF APPLIED ECOLOGY (2023)
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Hongchao Pan, Richard Gray, Jeremy Braybrooke, Christina Davies, Carolyn Taylor, Paul McGale, Richard Peto, Kathleen I. Pritchard, Jonas Bergh, Mitch Dowsett, Daniel F. Hayes
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Journal Club
P. Dovjak
ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE (2018)
The Breast Cancer Weight Loss (BWEL) trial: Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early-stage breast cancer (Alliance A011401).
Jennifer A. Ligibel, William Thomas Barry, Catherine M. Alfano, Dawn L. Hershman, Melinda L. Irwin, Marian Neuhouser, Cynthia A. Thomson, Linda Delahanty, Elizabeth Frank, Patricia Spears, Electra D. Paskett, Judith O. Hopkins, Vanessa Bernstein, Vered Stearns, Julia R. White, Thomas Wadden, Pamela Jean Goodwin, Lisa A. Carey, Ann Partridge, Eric P. Winer
JOURNAL OF CLINICAL ONCOLOGY (2018)
The effect of metformin on sex hormones in non diabetic breast cancer patients in CCTG MA.32: A Phase III randomized adjuvant trial of metformin versus placebo in addition to standard therapy.
Isabel Pimentel, Bingshu E. Chen, Ana Elisa Lohmann, Marguerite Ennis, Jennifer A. Ligibel, Lois E. Shepherd, Dawn L. Hershman, Vuk Stambolic, Ingrid A. Mayer, Timothy J. Hobday, Julie Lemieux, Alastair Mark Thompson, Priya Rastogi, Karen A. Gelmon, Timothy Joseph Whelan, Manuela Rabaglio-Poretti, Ryan Jo Dowling, Wendy R. Parulekar, Pamela Jean Goodwin
JOURNAL OF CLINICAL ONCOLOGY (2019)
Obesity and Breast Cancer: Expanding the Hypothesis Space
Ana Elisa Lohmann, Pamela J. Goodwin
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Diabetes and Cancer: Unraveling the Complexity
Pamela J. Goodwin
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial
Pamela J. Goodwin, Ryan J. O. Dowling, Marguerite Ennis, Bingshu E. Chen, Wendy R. Parulekar, Lois E. Shepherd, Margot J. Burnell, Rachel Vander Meer, Andrea Molckovsky, Anagha Gurjal, Karen A. Gelmon, Jennifer A. Ligibel, Dawn L. Hershman, Ingrid A. Mayer, Timothy J. Whelan, Timothy J. Hobday, Priya Rastogi, Manuela Rabaglio-Poretti, Julie Lemieux, Alastair M. Thompson, Daniel W. Rea, Vuk Stambolic
NPJ BREAST CANCER (2021)
Crown-like structures in breast adipose tissue of breast cancer patients: associations with CD68 expression, obesity, metabolic factors and prognosis
Martin C. Chang, Zohreh Eslami, Marguerite Ennis, Pamela J. Goodwin
NPJ BREAST CANCER (2021)
The Futility of Futility Analyses in Adjuvant Trials in Hormone Receptor-Positive Breast Cancer COMMENT
Ana Elisa Lohmann, Marguerite Ennis, Wendy R. Parulekar, Bingshu E. Chen, George Tomlinson, Pamela J. Goodwin
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)
Flashback Foreword: Anti-HER2 Monoclonal Antibody as a Single Agent
Pamela J. Goodwin
JOURNAL OF CLINICAL ONCOLOGY (2023)
Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin versus placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32).
Dawn L. Hershman, Bingshu E. Chen, Wendy R. Parulekar, Julie Lemieux, Jennifer A. Ligibel, Karen A. Gelmon, Timothy Joseph Whelan, Pamela Jean Goodwin
JOURNAL OF CLINICAL ONCOLOGY (2022)
Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo
Pamela J. Goodwin, Ryan J. O. Dowling, Marguerite Ennis, Bingshu E. Chen, Wendy R. Parulekar, Lois E. Shepherd, Karen A. Gelmon, Timothy J. Whelan, Jennifer A. Ligibel, Dawn L. Hershman, Ingrid A. Mayer, Timothy J. Hobday, Priya Rastogi, Manuela Rabaglio-Poretti, Julie Lemieux, Alastair M. Thompson, Daniel W. Rea, Vuk Stambolic
JNCI CANCER SPECTRUM (2021)
The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer
Pamela J. Goodwin, Roanne J. Segal, Michael Vallis, Jennifer A. Ligibel, Gregory R. Pond, Andre Robidoux, Brian Findlay, Julie R. Gralow, Som D. Mukherjee, Mark Levine, Kathleen I. Pritchard
NPJ BREAST CANCER (2020)
Association of obesity with breast cancer outcome in relation to cancer subtypes.
Ana Elisa Lohmann, Sara V. Soldera, Isabel Pimentel, Domen Ribnikar, Marguerite Ennis, Eitan Amir, Pamela Jean Goodwin
JOURNAL OF CLINICAL ONCOLOGY (2019)
Leptin-Receptor Expression in Luminal-Type Breast Carcinoma Is Associated with Pathologic Features of Diffuse Risk but Not with Tumor Proliferation
Blerta Starova, Mandi Rahimi, Marguerite Ennis, Ryan J. O. Dowling, Vuk Stambolic, Pamela J. Goodwin, Martin C. Chang
LABORATORY INVESTIGATION (2017)